Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing Radiotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-04

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study investigates the dynamic changes in plasma calcitonin gene-related peptide (CGRP) levels during radiotherapy and their association with radiotherapy-related pain in patients with head and neck malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury

NCT00178295

Brain Neoplasm

COMPLETED

Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.

NCT07011329

Nasopharyngeal Carcinoma (NPC)

ACTIVE_NOT_RECRUITING

Biomarkers for Prognosis of Glioblastoma (GBM)

NCT01493219

Glioblastoma

COMPLETED

Brain Metastases Study: Radiotherapy Fractionation Schemes in the Treatment of Brain Metastases

NCT00138788

Neoplasm Metastasis Brain Neoplasms

COMPLETED PHASE3

A Predictive Nomogram for Trismus After Radiotherapy for Head and Neck Cancer

NCT05777668

Trismus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Radiotherapy-related pain is a major clinical challenge that significantly affects the long-term quality of life and treatment adherence of patients with head and neck cancer. Current analgesic strategies offer limited efficacy, and reliable biomarkers for predicting pain risk are lacking. In recent years, calcitonin gene-related peptide (CGRP) has drawn increasing attention for its critical role in chronic pain regulation, as demonstrated in various pain models. However, no systematic studies have yet investigated the expression patterns and clinical relevance of CGRP in radiotherapy-induced pain among patients with head and neck malignancies. This single-center, prospective observational study aims to enroll patients with head and neck cancer receiving either definitive or postoperative adjuvant radiotherapy. Plasma samples will be collected before, during, and after radiotherapy for measurement of CGRP levels. Pain intensity will be simultaneously assessed using the Numeric Rating Scale (NRS) and the Brief Pain Inventory-Short Form (BPI-SF). The study seeks to explore the dynamic changes in plasma CGRP levels throughout the radiotherapy course and to analyze their correlation with patient-reported pain, thereby providing potential insights into biomarker-based pain prediction and management strategies in this patient population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years

Histologically confirmed head and neck malignancy

Planned to receive definitive or postoperative adjuvant radiotherapy

Radiotherapy duration ≥ 4 weeks, with irradiation field involving the oral cavity, pharynx, or neck region

Able and willing to provide written informed consent

Able to complete pain assessments and blood sample collection

Exclusion Criteria

* History of significant chronic pain prior to radiotherapy (e.g., postherpetic neuralgia, rheumatoid arthritis)

Presence of uncontrolled hypertension, diabetes, or migraines

Presence of other active malignancies or major systemic diseases (e.g., severe hepatic or renal dysfunction)

Currently receiving or recently received treatments that may significantly affect pain perception (e.g., opioids, antidepressants)

Pregnant or breastfeeding

Inability to complete follow-up or poor treatment compliance

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No